Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Sanofi”

Teriflunomide Observational Effectiveness StudyCompleted
NCT02490982N/AUpdated Aug 18, 2021
Sponsor: Centre hospitalier de l'Université de Montréal (CHUM)
Relapsing Remitting Multiple Sclerosis
Canada
Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Study Of NK Cell Transplantation In Newly Diagnosed Acute Myeloid LeukemiaCompleted
NCT00703820Phase 3Updated Aug 10, 2021
Sponsor: St. Jude Children's Research Hospital
Acute Myeloid Leukemia
United States, Singapore
Comparison of SoloSTAR With a Syringe-administered Glargine Insulin in Diabetic Patients From the HospitalCompleted
NCT01203774Phase 4Updated Aug 6, 2021
Sponsor: University of Colorado, Denver
Diabetes
United States
Toujeo Versus NPH Self-titration StudyCompleted
NCT03389490Phase 4Updated Aug 3, 2021
Sponsor: Elaine Chow
Diabetes Mellitus, Type 2
Hong Kong
Sleep Medical Treatment in MS Patients Suffering From FatigueTerminated
NCT03759249NAUpdated Aug 3, 2021
Sponsor: Charite University, Berlin, Germany
Multiple Sclerosis · Fatigue
Germany
North American Acute Coronary Syndrome (ACS) Reflective III PilotCompleted
NCT03994575N/AUpdated Jul 27, 2021
Sponsor: Canadian Heart Research Centre
Dyslipidemias · Acute Coronary Syndrome
Canada
Alglucosidase Alfa Pompe Safety Sub-RegistryCompleted
NCT01710813N/AUpdated Jul 13, 2021
Sponsor: Genzyme, a Sanofi Company
Pompe Disease
United States, Belgium, Czechia, Germany, Italy +1 more
SAR650984, Pomalidomide and Dexamethasone in Combination in RRMM PatientsCompleted
NCT02283775Phase 1Updated Jul 9, 2021
Sponsor: Sanofi
Plasma Cell Myeloma
United States
Identification of Tongue Involvement in Late-Onset Pompe DiseaseCompleted
NCT02765828N/AUpdated Jul 6, 2021
Sponsor: Duke University
Myopathy · Neuropathy · Glycogen Storage Disease Type II (Late-onset Pompe Disease)
United States
Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Intravenous Oxaliplatin Plus Irinotecan in Patients With Unresectable Hepatic Metastases From Colorectal CancerCompleted
NCT00695201Phase 1Updated Jul 1, 2021
Sponsor: Memorial Sloan Kettering Cancer Center
Colon Cancer · Rectal Cancer
United States
Study in Participants With Homozygous Familial Hypercholesterolemia (HoFH)Completed
NCT03156621Phase 3Updated Jun 29, 2021
Sponsor: Regeneron Pharmaceuticals
Homozygous Familial Hypercholesterolemia
United States, Austria, Canada, Czechia, France +8 more
Safety and Efficacy Study of Sotagliflozin on Glucose Control in Participants With Type 2 Diabetes, Moderate Impairment of Kidney Function, and Inadequate Blood Sugar ControlCompleted
NCT03242252Phase 3Updated Jun 25, 2021
Sponsor: Lexicon Pharmaceuticals
Type 2 Diabetes Mellitus · Chronic Kidney Disease Stage 3
United States, Argentina, Brazil, Canada, Colombia +11 more
Efficacy and Bone Safety of Sotagliflozin 400 and 200 mg Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic ControlTerminated
NCT03386344Phase 3Updated Jun 25, 2021
Sponsor: Lexicon Pharmaceuticals
Type 2 Diabetes Mellitus
United States, Australia, Canada, Mexico, New Zealand +3 more
A Study to Evaluate Safety and Effects of Sotagliflozin 400 and 200 mg on Glucose Control in Participants With Type 2 Diabetes, Severe Impairment of Kidney Function and Inadequate Blood Sugar ControlCompleted
NCT03242018Phase 3Updated Jun 25, 2021
Sponsor: Lexicon Pharmaceuticals
Type 2 Diabetes Mellitus · Chronic Kidney Disease Stage 4
United States, Argentina, Brazil, Colombia, Germany +10 more
Study of the Efficacy and Safety of Ferrlecit in the Maintenance Dosing in Hemodialysis Patients.Terminated
NCT00223938Phase 4Updated Jun 24, 2021
Sponsor: Sanofi
Anemia
United States
Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus Not Currently Treated With Antidiabetic TherapyCompleted
NCT02926937Phase 3Updated Jun 21, 2021
Sponsor: Lexicon Pharmaceuticals
Type 2 Diabetes Mellitus
United States, Canada, Mexico
Long Term Safety Study of PRALUENTTerminated
NCT03694197Phase 4Updated Jun 15, 2021
Sponsor: Regeneron Pharmaceuticals
Heterozygous Familial Hypercholesterolemia · Non-familial Hypercholesterolemia
United States, Bulgaria, Estonia, Russia, South Africa +1 more
Complement Activation in the Lysosomal Storage DisordersWithdrawn
NCT04189601N/AUpdated Jun 7, 2021
Sponsor: Melbourne Health
Fabry Disease · Gaucher Disease · Niemann-Pick Disease, Type C · Lysosomal Storage Diseases
Australia
Study by Magnetic Resonance Imaging in the Progressive Forms of Multiple SclerosisTerminated
NCT02580669NAUpdated May 18, 2021
Sponsor: University Hospital, Montpellier
Progressive Multiple Sclerosis · Multiple Sclerosis, Relapsing-Remitting
France
Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus on Background of MetforminCompleted
NCT02926950Phase 3Updated May 11, 2021
Sponsor: Lexicon Pharmaceuticals
Type 2 Diabetes Mellitus
United States, Canada, Hungary, Slovakia
Efficacy and Safety of Sotagliflozin Versus Glimepiride and Placebo in Participants With Type 2 Diabetes Mellitus That Are Taking Metformin MonotherapyCompleted
NCT03332771Phase 3Updated May 11, 2021
Sponsor: Lexicon Pharmaceuticals
Type 2 Diabetes Mellitus
United States, Bulgaria, Hungary, Slovakia
Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With MetforminCompleted
NCT03351478Phase 3Updated May 11, 2021
Sponsor: Lexicon Pharmaceuticals
Type 2 Diabetes Mellitus
United States, Bulgaria, Canada, Czechia, France +7 more
Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking Insulin Alone or With Other Oral Antidiabetic AgentsCompleted
NCT03285594Phase 3Updated May 11, 2021
Sponsor: Lexicon Pharmaceuticals
Type 2 Diabetes Mellitus
United States, Bulgaria, Canada, Czechia, France +3 more
Safety, Tolerability and Pharmacodynamic Activity of Sotagliflozin in Hemodynamically Stable Participants With Worsening Heart FailureTerminated
NCT03292653Phase 2Updated May 11, 2021
Sponsor: Lexicon Pharmaceuticals
Cardiac Failure Aggravated
United States, Canada, Netherlands
Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus on Background of Sulfonylurea Alone or With MetforminCompleted
NCT03066830Phase 3Updated May 11, 2021
Sponsor: Lexicon Pharmaceuticals
Type 2 Diabetes Mellitus
United States, Bulgaria, Estonia, Hungary, Poland +5 more

Previous page Next page